196 related articles for article (PubMed ID: 23265701)
1. Outcome of second-line chemotherapy for biliary tract cancer.
Bridgewater J; Palmer D; Cunningham D; Iveson T; Gillmore R; Waters J; Harrison M; Wasan H; Corrie P; Valle J
Eur J Cancer; 2013 Apr; 49(6):1511. PubMed ID: 23265701
[No Abstract] [Full Text] [Related]
2. Response to letter 'outcome of second-line chemotherapy for biliary tract cancer'.
Walter T; Horgan AM; McNamara M; McKeeve L; Min T; Hedley D; Serra S; Krzyzanowska MK; Chen E; Mackay H; Feld R; Moore M; Knox JJ
Eur J Cancer; 2013 Apr; 49(6):1512-3. PubMed ID: 23260192
[No Abstract] [Full Text] [Related]
3. Second-line Chemotherapy Prolongs Survival in Real World Patients With Advanced Biliary Tract and Gallbladder Cancers: A Multicenter Retrospective Population-based Cohort Study.
Zaidi A; Chandna N; Narasimhan G; Moser M; Haider K; Chalchal H; Shaw J; Ahmed S
Am J Clin Oncol; 2021 Mar; 44(3):93-98. PubMed ID: 33350678
[TBL] [Abstract][Full Text] [Related]
4. Improvement of prognosis for unresectable biliary tract cancer.
Sasaki T; Isayama H; Nakai Y; Takahara N; Sasahira N; Kogure H; Mizuno S; Yagioka H; Ito Y; Yamamoto N; Hirano K; Toda N; Tada M; Omata M; Koike K
World J Gastroenterol; 2013 Jan; 19(1):72-7. PubMed ID: 23326165
[TBL] [Abstract][Full Text] [Related]
5. Current status of chemotherapy for the treatment of advanced biliary tract cancer.
Sasaki T; Isayama H; Nakai Y; Koike K
Korean J Intern Med; 2013 Sep; 28(5):515-24. PubMed ID: 24009445
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy and antiangiogenics in biliary tract cancer.
Goyal L; Chong DQ; Duda DG; Zhu AX
Lancet Oncol; 2015 Aug; 16(8):882-3. PubMed ID: 26179202
[No Abstract] [Full Text] [Related]
7. Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study.
Larsen FO; Markussen A; Diness LV; Nielsen D
Oncology; 2018; 94(1):19-24. PubMed ID: 28930749
[TBL] [Abstract][Full Text] [Related]
8. Role of chemotherapy in treatments for biliary tract cancer.
Furuse J; Kasuga A; Takasu A; Kitamura H; Nagashima F
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):337-41. PubMed ID: 22456744
[TBL] [Abstract][Full Text] [Related]
9. Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow.
Rizzo A; Ricci AD; Tober N; Nigro MC; Mosca M; Palloni A; Abbati F; Frega G; DE Lorenzo S; Tavolari S; Brandi G
Anticancer Res; 2020 Jun; 40(6):3013-3030. PubMed ID: 32487595
[TBL] [Abstract][Full Text] [Related]
10. Second-line chemotherapy in advanced biliary cancer: the present now will later be past.
Vivaldi C; Fornaro L; Cereda S; Aprile G; Santini D; Silvestris N; Lonardi S; Leone F; Milella M; Brandi G; Vasile E
Ann Oncol; 2014 Dec; 25(12):2443-2444. PubMed ID: 25122694
[No Abstract] [Full Text] [Related]
11. Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer.
Jung JH; Lee HS; Jo JH; Cho IR; Chung MJ; Bang S; Park SW; Song SY; Park JY
Chemotherapy; 2017; 62(6):361-366. PubMed ID: 28848173
[TBL] [Abstract][Full Text] [Related]
12. Comparative outcomes of elderly and non-elderly patients receiving first-line palliative chemotherapy for advanced biliary tract cancer.
Kou T; Kanai M; Ikezawa K; Ajiki T; Tsukamoto T; Toyokawa H; Yazumi S; Terajima H; Furuyama H; Nagano H; Ikai I; Kuroda N; Awane M; Ochiai T; Takemura S; Miyamoto A; Kume M; Ogawa M; Takeda Y; Taira K; Ioka T
J Gastroenterol Hepatol; 2014 Feb; 29(2):403-8. PubMed ID: 23869919
[TBL] [Abstract][Full Text] [Related]
13. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ
Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436
[TBL] [Abstract][Full Text] [Related]
14. Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers.
Mathers B; Abadi S; Davies JM; McIntyre C; Ho C
J Oncol Pharm Pract; 2023 Sep; 29(6):1381-1386. PubMed ID: 36320173
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma.
Sun W; Patel A; Normolle D; Patel K; Ohr J; Lee JJ; Bahary N; Chu E; Streeter N; Drummond S
Cancer; 2019 Mar; 125(6):902-909. PubMed ID: 30561756
[TBL] [Abstract][Full Text] [Related]
16. Impact of Itraconazole After First-line Chemotherapy on Survival of Patients with Metastatic Biliary Tract Cancer.
Tsubamoto H; Sonoda T; Ikuta S; Tani S; Inoue K; Yamanaka N
Anticancer Res; 2015 Sep; 35(9):4923-7. PubMed ID: 26254389
[TBL] [Abstract][Full Text] [Related]
17. Surgical treatment and adjuvant chemotherapy for patients with biliary tract cancer: single institution experience of 100 patients.
Harada N; Shirabe K; Yoshizumi T; Ikegami T; Uchiyama H; Soejima Y; Yamashita Y; Saeki H; Oki E; Kawanaka H; Morita M; Ikeda T; Matsuura H; Okadome K; Maehara Y
Fukuoka Igaku Zasshi; 2013 Dec; 104(12):539-48. PubMed ID: 24693682
[TBL] [Abstract][Full Text] [Related]
18. Second-line therapies in advanced biliary tract cancers.
Tella SH; Kommalapati A; Borad MJ; Mahipal A
Lancet Oncol; 2020 Jan; 21(1):e29-e41. PubMed ID: 31908303
[TBL] [Abstract][Full Text] [Related]
19. FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience.
Moretto R; Raimondo L; De Stefano A; Cella CA; Matano E; De Placido S; Carlomagno C
Anticancer Drugs; 2013 Oct; 24(9):980-5. PubMed ID: 23928570
[TBL] [Abstract][Full Text] [Related]
20. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.
Kus T; Aktas G; Kalender ME; Sevinc A; Camci C
J Gastrointest Cancer; 2017 Jun; 48(2):170-175. PubMed ID: 27714651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
